Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 10Enrolling by invitation 3Completed 2Withdrawn 1Terminated 1Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 51Breast Neoplasms 40Colorectal Neoplasms 26Prostatic Neoplasms 22Lung Neoplasms 18Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 15Stomach Neoplasms 14Brain Neoplasms 11Hematologic Neoplasms 10Pancreatic Neoplasms 9Colonic Neoplasms 9Uterine Cervical Neoplasms 8Urinary Bladder Neoplasms 8Lymphoma, Follicular 8Head and Neck Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 7Melanoma 7Liver Neoplasms 7Leukemia, Myeloid, Acute 7Disease 7Anxiety Disorders 7Myasthenia Gravis 6Multiple Myeloma 6Barrett Esophagus 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Rectal Neoplasms 5Lymphoma, Non-Hodgkin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Enrolling by invitation × Adenoviridae Infections × 1 year × Clear all
NCT06763965 2026-03-23

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1/2 Enrolling by invitation
30 enrolled
CNS

Adenoviridae Infections, Glioma

NCT06215846 2025-11-26

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1 Enrolling by invitation
12 enrolled

Adenoviridae Infections

NCT06027879 2025-06-25

Gamma Capture

University of Pittsburgh

Phase 1/2 Enrolling by invitation
25 enrolled

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡